2015
Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC).
Curigliano G, Aftimos P, Dees E, LoRusso P, Pegram M, Awada A, Huang B, Cesari R, Jiang Y, Shaik M, Kern K, Locatelli M. Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2015, 33: 1068-1068. DOI: 10.1200/jco.2015.33.15_suppl.1068.Peer-Reviewed Original Research
2012
588 A First-in-patient Phase I Study of the Novel Gamma Secretase Inhibitor PF-03084014 in Patients with Advanced Solid Tumor Malignancies
Messersmith W, LoRusso P, Cleary J, Dasari A, Huang B, Shaik N, Cesari R, McLachlan K, Kern K, Shapiro G. 588 A First-in-patient Phase I Study of the Novel Gamma Secretase Inhibitor PF-03084014 in Patients with Advanced Solid Tumor Malignancies. European Journal Of Cancer 2012, 48: 180. DOI: 10.1016/s0959-8049(12)72385-7.Peer-Reviewed Original Research
2011
A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors.
Messersmith W, LoRusso P, Cleary J, Dasari A, Zhang X, Shaik M, Courtney R, Randolph S, Shapiro G. A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2011, 29: 3100-3100. DOI: 10.1200/jco.2011.29.15_suppl.3100.Peer-Reviewed Original Research